New drug APSTZD aims to improve sleep in insomnia patients
NCT ID NCT07420816
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial tests a new drug called APSTZD for people with chronic insomnia. About 222 adults aged 18-64 will receive either APSTZD, an active comparator (Stilnox CR), or a placebo. The main goal is to see if APSTZD reduces time awake after falling asleep, measured by overnight sleep studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- APSTZD
- What this could lead to
- If successful, APSTZD could offer a new treatment option for people with chronic insomnia, improving sleep quality.
- What could go wrong
- This is an early Phase II trial with a small number of participants. The drug may not prove more effective than existing treatments or placebo, and side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSOMNIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UNIFAG - Casa Nossa Senhora da PAZ -ASF
Bragança Paulista, São Paulo, 12916-900, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Light therapy during sleep may offer a Drug-Free path to better rest
- Mind over bladder: can sleep training curb nighttime urges?
- Can an ancient herbal formula unlock better sleep and weight loss?
- Could a simple sleep guide ease insomnia in lung disease?
- Digital sleep coaching for seniors: a new hope for insomnia?
- Fixing sleep, fortifying hearts: a new trial tests the link